The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion.
SOUTH SAN FRANCISCO, CA, USA I November 25, 2024 I Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically ...
WARREN, NJ, USA I6, 2024 I PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease ...
Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right ...